Cytokine induction of selectin ligands on cells

Abstract

Methods and compositions for treating cells with cytokines are provided herein.

What is claimed is: 
     
         1 . A method for increasing cell surface expression or activity of an E-selectin ligand on a myeloid cell comprising, contacting the myeloid cell with granulocyte colony stimulating factor (G-CSF) and a sialidase inhibitor, thereby increasing cell surface expression or activity of an E-selectin ligand on the cell. 
     
     
         2 . The method of  claim 1 , wherein a plurality of myeloid cells are provided. 
     
     
         3 . The method of  claim 1 , wherein the myeloid cell is autologous. 
     
     
         4 . The method of  claim 1 , wherein the myeloid cell is allogeneic. 
     
     
         5 . The method of  claim 1 , wherein the myeloid cell is provided ex vivo. 
     
     
         6 . The method of  claim 1 , wherein the myeloid cell is contacted with G-CSF in vitro. 
     
     
         7 . The method of  claim 1 , wherein the E-selectin ligand is a hematopoietic cell E-/L-selectin Ligand (HCELL) polypeptide. 
     
     
         8 . The method of  claim 1 , wherein said method increases the expression of a HECA-452-reactive epitope on the cell. 
     
     
         9 . The method of  claim 1 , wherein the cell is treated ex vivo, and wherein the method further comprises administering the cell to a subject in need thereof. 
     
     
         10 . The method of  claim 8 , wherein the cell is administered to a subject as part of treatment with hematopoietic stem cell transplantation. 
     
     
         11 . The method of  claim 8 , wherein the cell is administered to a subject who is in need of treatment for tissue injury. 
     
     
         12 . The method of  claim 1 , wherein the sialidase inhibitor is 2-deoxy-2,3-dehydro-N-acetyl-neuraminic acid (DANA). 
     
     
         13 . The method of  claim 1 , wherein the cell is administered to a subject as part of treatment with hematopoietic stem cell transplantation. 
     
     
         14 . The method of  claim 1 , wherein the cell is administered to a subject as part of treatment for infection. 
     
     
         15 . The method of  claim 1 , wherein the cell is administered to a subject who is in need of treatment for tissue injury. 
     
     
         16 . The method of  claim 1 , wherein the cell is a native human myeloid cell. 
     
     
         17 . The method of  claim 1 , wherein the cell is a native human immature myeloid cell. 
     
     
         18 . The method of  claim 1 , wherein the cell is a myeloid cell and wherein the method increases the ability of the cell to migrate to endothelial beds expressing E-selectin.